Sheldon Koenig compensation by year
Esperion Therapeutics Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $683,333 | $720,833 | $745,833 | $770,833 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $549,840 | $422,100 | $930,700 | $1,260,000 |
| Option awards | $2,052,139 | $1,267,661 | $982,162 | $847,929 |
| Non-equity incentive | $500,500 | $541,938 | $487,500 | $639,375 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $13,600 | $16,033 | $29,045 | $17,375 |
| Total | $3,799,412 | $2,968,565 | $3,175,240 | $3,535,512 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Esperion Therapeutics, Inc. DEF 14A filed April 16, 2026, accession 0001628280-26-025499, and prior-year filings.
How this page was built: the Esperion Therapeutics, Inc. filed document, accession 0001628280-26-025499. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 682,500 | $2,525,250 | — |
| RSU | 255,375 | $944,888 | — |
| RSU | 32,818 | $121,427 | — |
| RSU | 7,250 | $26,825 | — |
| Option | 139,068 | — | $4.02 |
| Option | 30,750 | — | $4.74 |
| Option | 611,814 | — | $1.50 |
| Option | 361,125 | — | $2.05 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Esperion Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
5 Form 4 lines since the FY2025 proxy (filed April 16, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-13 | Disposition to the issuer derivative | — | 753,000 | — | 0 |
| 2026-07-13 | Disposition to the issuer derivative | — | 647,460 | — | 0 |
| 2026-07-13 | Disposition to the issuer | — | 2,121,094 | — | 0 |
| 2026-07-13 | Disposition to the issuer derivative | — | 642,000 | — | 0 |
| 2026-06-17 | Sale | — | 53,588 | $3.15 | 2,119,111 |
The 5 most recent of 5 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Esperion Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sheldon Koenig · this page | President and Chief Executive Officer | $3,535,512 |
| John Harlow | Chief Commercial Officer | $2,813,103 |
| Benjamin Halladay | Chief Financial Officer | $1,351,935 |
Board service
Esperion Therapeutics board · FY2023–FY2025How this board is paid
Company policy: Esperion Therapeutics pays directors a $50,000 cash retainer. As stated in Esperion Therapeutics's FY2025 proxy.
The full Esperion Therapeutics compensation record
free company briefThis page is one person within Esperion Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Esperion Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Esperion Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Esperion Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.